Human kidney thiopurine methyltransferase. Photoaffinity labeling with S-adenosyl-L-methionine.
Thiopurine methyltransferase (TPMT) catalyzes the S-methylation of heterocyclic and aromatic sulfhydryl compounds such as the thiopurine drug 6-mercaptopurine (6-MP). TPMT activity in human tissue is regulated by a common genetic polymorphism, and "pharmacogenetic" variation in TPMT activity is an important factor in individual differences in thiopurine drug metabolism, toxicity and therapeutic efficacy. Human renal tissue contains two isozymes of TPMT, Peak I and Peak II, that can be separated by ion exchange chromatography. Our experiments were performed to determine whether S-adenosyl-L-methionine (Ado-Met), the methyl donor for the TPMT reaction, could be used as a photoaffinity ligand for these isozymes as one step in the study of the molecular basis for the TPMT genetic polymorphism. When [3H-methyl]Ado-Met and partially purified preparations of either isozyme of human kidney TPMT were exposed to ultraviolet light at 254 nm, followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, a 35 kDa protein was the predominant species that was radioactively labeled. The same 35 kDa protein was photoaffinity labeled with [14C-carboxyl]Ado-Met, demonstrating that labeling involved covalent binding of Ado-Met rather than methylation of the protein. TPMT enzymatic activity co-eluted with the 35 kDa protein during sequential DEAE ion exchange, gel filtration and hydroxylapatite chromatography. Inhibitors of TPMT enzymatic activity including S-adenosyl-L-homocysteine, sinefungin, 6-methylmercaptopurine and 3,4-dimethoxy-5-hydroxybenzoic acid inhibited photoaffinity labeling of the 35 kDa protein in preparations of both TPMT Peak I and Peak II isozymes in a concentration-dependent fashion, as did 6-MP, the methyl acceptor substrate for the TPMT reaction. All of these results were compatible with the conclusion that the 35 kDa protein was TPMT. Photoaffinity labeling of TPMT with [3H]Ado-Met should make it possible to purify the enzyme to homogeneity and to study amino acid sequences at or near its active site.
Van Loon
J A
JA
Department of Pharmacology, Mayo Clinic/Mayo Foundation, Rochester, MN 55905.
Szumlanski
C L
CL
Weinshilboum
R M
RM
D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D000345:Affinity Labels; D001345:Autoradiography; D002852:Chromatography, Ion Exchange; D005707:Gallic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D007527:Isoenzymes / Q000032:analysis; D007668:Kidney / Q000201:enzymology*; D015122:Mercaptopurine / Q000494:pharmacology; D008780:Methyltransferases / Q000032:analysis* / Q000737:chemistry / Q000235:genetics; D010782:Photolysis; D011110:Polymorphism, Genetic; D012435:S-Adenosylhomocysteine / Q000494:pharmacology; D012436:S-Adenosylmethionine / Q000031:analogs & derivatives / Q000737:chemistry
D000345:Affinity Labels; D007527:Isoenzymes; C039753:3,4-dimethoxy-5-hydroxybenzoic acid; D005707:Gallic Acid; D012436:S-Adenosylmethionine; D012435:S-Adenosylhomocysteine; D015122:Mercaptopurine; D008780:Methyltransferases; C022745:thiopurine methyltransferase; D000241:Adenosine; C006235:sinefungin